Tirzepatide, a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), may indirectly affect menstrual cycles in some women
The measurements were then converted into a percentage using the following formula: % of wound remaining = (measurement at time 12 hours/measurement at time 0 hours) 100
For comparison, a B12 tablet leaves you with only 1.2% of B12 in the tablet
Its studied for its ability to promote tissue healing, regeneration of injured tissue, accelerated repair and wound healing, nerve damage healing, and regulate inflammation
The rate of weight loss mattersmore gradual reduction may cause fewer menstrual disruptions than rapid weight loss, though tirzepatide-induced weight loss occurs relatively quickly compared to lifestyle modification alone